Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Core Insights - Gain Therapeutics, Inc. is participating in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, where the management team will engage in a fireside chat and one-on-one meetings [1][2] Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric therapies [3] - The lead drug candidate, GT-02287, is currently in a Phase 1b clinical trial for treating Parkinson's disease, with potential applications in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease [3] - The company has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [3] Technology and Approach - Gain Therapeutics employs a unique approach to discover novel allosteric small molecule modulators that can restore or disrupt protein function [4] - Utilizing the advanced Magellan™ platform, the company aims to accelerate drug discovery and develop disease-modifying treatments for challenging disorders, including neurodegenerative diseases and rare genetic disorders [4]